Dp1.Hno

DP1.HNO has a debt-to-equity ratio of 1.04, indicating a relatively balanced capital structure with a moderate reliance on debt financing. The company's liquidity position is assessed as medium, with a current ratio of 1.32, suggesting it can cover its short-term obligations but with limited buffer. Despite a negative operating cash flow of -142.38 billion VND, the company maintains a free cash flow of 75.60 billion VND, which supports ongoing operations and potential reinvestment.

In terms of profitability, DP1.HNO reports a return on equity (ROE) of 19.18% and a return on assets (ROA) of 5.87%. These figures are strong relative to the industry median for ROE and ROA, which typically hover around 12-15% and 4-6%, respectively, for pharmaceutical firms. The company's gross profit of 288.84 billion VND and operating income of 102.05 billion VND further underscore its ability to generate profit from core operations.

The company's revenue is concentrated in a single business segment, with no disclosed geographic diversification. This lack of diversification increases exposure to regional economic and regulatory risks. The absence of segmental or geographic breakdown in the financial data suggests a need for further transparency in the company's reporting.

DP1.HNO's growth trajectory is not explicitly outlined in the available data, but the company's free cash flow and operating income suggest a stable financial position. The absence of a detailed outlook for the current or next fiscal year limits the ability to assess future growth potential. Historical revenue data indicates a consistent revenue stream, but without forward-looking guidance, it is difficult to determine the direction of future performance.

The risk assessment for DP1.HNO highlights a medium liquidity risk and a low dilution risk. The company's net cash position is negative after accounting for total debt, which could impact its ability to meet long-term obligations. However, the low dilution risk suggests that the company is not currently issuing shares at a rate that would significantly dilute existing shareholders.

Recent events and filings do not provide specific details on the company's strategic initiatives or major developments. The absence of recent transcripts or filings limits the ability to assess the company's current strategic direction and management commentary. The company's financial performance and risk profile suggest a need for continued monitoring of its liquidity and capital structure.